Trials / Terminated
TerminatedNCT04171765
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis
A Phase II, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Patients With Non-Alcoholic Steatohepatitis
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 46 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the efficacy, safety, and pharmacokinetics of BFKB8488A compared to placebo in participants with non-alcoholic steatohepatitis (NASH).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Participants will receive subcutaneous (SC) placebo matched to BFKB8488A. |
| DRUG | BFKB8488A | Participants will receive subcutaneous (SC) BFKB8488A. |
Timeline
- Start date
- 2020-09-30
- Primary completion
- 2023-01-23
- Completion
- 2023-01-23
- First posted
- 2019-11-21
- Last updated
- 2024-04-16
- Results posted
- 2024-04-16
Locations
53 sites across 5 countries: United States, Belgium, France, Puerto Rico, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04171765. Inclusion in this directory is not an endorsement.